Elevated plasma TGF-beta1 in renal diseases: cause or consequence?

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Cytokine

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 10880255
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection.

  1999cited by this paper
• Role of transforming growth factor-beta 1 in invasion and metastasis in gastric carcinoma.

  1999cited by this paper
• TGF-beta1 alters the healing of cutaneous fetal excisional wounds.

  1999cited by this paper
• Transforming growth factor beta 1 is significantly elevated in plasma of patients suffering from renal cell carcinoma.

  1998cited by this paper
• Potential role of TGF-beta in diabetic nephropathy.

  1998cited by this paper
• Aggregating human platelets stimulate the expression of thrombin receptors in cultured vascular smooth muscle cells via the release of transforming growth factor-beta1 and platelet-derived growth factorAB.

  1997cited by this paper
• Serum transforming growth factor-beta1 in patients with renal cell carcinoma.

  1997cited by this paper
• Renal Cell Carcinomas Produce IL-6, IL-10, IL-11, and TGF-β1 in Primary Cultures and Modulate T Lymphocyte Blast Transformation

  1997cited by this paper
• A detailed protocol for the measurement of TGF-beta1 in human blood samples.

  1997cited by this paper
• Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease.

  1996cited by this paper
• Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions.

  1995cited by this paper
• Elevated D-glucose concentrations modulate TGF-beta 1 synthesis by human cultured renal proximal tubular cells. The permissive role of platelet-derived growth factor.

  1995cited by this paper
• Transforming growth factor beta 1 inhibits interleukin-10 mRNA expression and production in pokeweed mitogen-stimulated peripheral blood mononuclear cells and T cells.

  1995cited by this paper
• Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer.

  1995cited by this paper
• Selective depression of T‐lymphocyte subsets in gastric cancer patients: An implication of immunotherapy

  1994cited by this paper
• Transforming growth factor-beta 1 (TGF-beta 1) inhibits DNA synthesis of PWM-stimulated PBMC via suppression of IL-2 and IL-6 production.

  1994cited by this paper
• Intraglomerular expression of transforming growth factor‐beta 1 (TGF‐β1) mRNA in patients with glomerulonephritis: quantitative analysis by competitive polymerase chain reaction

  1994cited by this paper
• Improved sandwich enzyme-linked immunosorbent assays for transforming growth factor beta 1.

  1993cited by this paper
• Immunohistochemical demonstration of growth factors, TGF-alpha, TGF-beta, IGF-I and neu oncogene product in benign and malignant human breast tissues.

  1990cited by this paper
• The expression of the platelet-derived and transforming growth factor genes in human nonsmall lung cancer cell lines is related to tumor stroma formation in nude mice tumors.

  1988cited by this paper

• Transforming Growth Factor‐β (TGF‐β) Levels and Neutrophil‐to‐Lymphocyte (NLR) and Platelet‐to‐Lymphocyte Ratios (PLR) in Patients With Chronic Kidney Disease (CKD) Undergoing Maintenance Hemodialysis

  2025cites this paper
• A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma

  2023cites this paper
• Downregulation of the endothelial histone demethylase JMJD3 is associated with neointimal hyperplasia of arteriovenous fistulas in kidney failure

  2022cites this paper
• Evaluating the Serum Transforming Growth Factor-Beta 1 Level in Chronic Kidney Disease Caused by Glomerulonephritis

  2021cites this paper
• Can Tumor Necrosis Factor-α and Interleukin-6 Be Used as Prognostic Markers of Infection following Ureteroscopic Lithotripsy?

  2014cites this paper
• Evaluation of TGF-β1, CCL5/RANTES and sFas/Apo-1 urine concentration in children with ureteropelvic junction obstruction

  2013cites this paper
• Monitoring peri-operative immune suppression in renal cancer patients.

  2011cites this paper
• The Role of Residual Gadolinium in the Induction of Nephrogenic Systemic Fibrosis-Like Skin Lesions in Rats

  2011cites this paper
• TGF-beta and microvessel homeostasis.

  2010cites this paper
• Is Serum Transforming Growth Factor beta-1 Superior to Serum Creatinine for assessing Renal Failure and Renal Transplant Rejection

  2009cites this paper
• Laminin and transforming growth factor beta-1 in children with vesicoureteric reflux

  2008cites this paper
• Analysis of the concentration of chosen parameters in urine of children with obstructive uropathy — preliminary report

  2007cites this paper
• Enoxaparin but not unfractionated heparin causes a dose-dependent increase in plasma TGF-beta 1 during haemodialysis: a cross-over study.

  2007cites this paper
• Transforming growth factor-beta downregulates interleukin-2-induced phosphorylation of signal transducer and activator of transcription 5 in human renal cell carcinoma.

  2007cites this paper
• TGF-β1 and Endothelial/Tissue Injury With High-dose Intravenous Iron Therapy in Renal Failure: Evidence or Perception?

  2006cites this paper
• Molecular Pathogenetics of Renal Cancer

  2006cites this paper
• Profibrotic cytokines and lymphocyte proliferation in stable renal allograft recipients treated with or without cyclosporine A.

  2006cites this paper
• Systemic mediators induce fibrogenic effects in normal liver after partial bile duct ligation

  2006cites this paper
• Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide III. Action on human megakaryocytopoiesis: focus on essential thrombocythemia.

  2004cites this paper
• Serum concentration of transforming growth factor (TGF)-beta 1 does not predict advanced liver fibrosis in children with chronic hepatitis B.

  2004cites this paper
• Expression of transforming growth factor β in renal cell carcinoma and matched non-involved renal tissue

  2004cites this paper
• Carboxy‐terminal fragment of osteogenic growth peptide in vitro increases bone marrow cell density in idiopathic myelofibrosis

  2003cites this paper
• Growth factors, cytokines, chemokines and neuropeptides in the modeling of T cells. Part II: Data tables of normal values in man.

  2003cites this paper
• Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology

  2003cites this paper
• Nephrogenic Fibrosing Dermopathy: An Unusual Skin Condition Associated with Kidney Disease

  2003influential citation
• Transforming-Growth-Faktor β1 beim Nierenzellkarzinom

  2003cites this paper
• Cadmium- and mercury-induced intercellular adhesion molecule-1 expression in immortalized proximal tubule cells: evidence for a role of decreased transforming growth factor-beta1.

  2002cites this paper
• [Local immune tolerance mechanisms in kidney cancer].

  2002cites this paper
• Understanding familial and non-familial renal cell cancer.

  2002cites this paper
• TGF-beta1 in patients with renal cell carcinoma.

  2002cites this paper
• TGF-β1 in patients with renal cell carcinoma

  2002cites this paper
• Disruption of a novel MFS transporter gene, DIRC2, by a familial renal cell carcinoma-associated t(2;3)(q35;q21).

  2002cites this paper
• Literature Watch

  2001cites this paper
• Literature Watch

  2001cites this paper
• Novel therapies for renal cell carcinoma

  2001cites this paper